Enfermedad del ligamento cruzado craneal (LCC) en perros
CCL disease, CCL rupture, cranial cruciate ligament rupture, CrCL rupture, cruciate disease, torn knee ligament in dogs, canine ACL tear (informal — the dog equivalent of the human ACL), stifle instability
El ligamento cruzado craneal es una banda que está dentro de la rodilla de su perro: evita que la tibia (el hueso de la pierna) se deslice hacia adelante por debajo del fémur y evita que la rodilla gire demasiado. En los perros casi nunca se rompe de golpe por un accidente: por lo general se va desgastando poco a poco, así que su mascota puede cojear de vez en cuando durante semanas antes de que el ligamento falle por completo. ANTES DE CUALQUIER OTRA COSA: nunca le dé a su perro medicamentos para el dolor de uso humano. El ibuprofeno, el naproxeno, la aspirina y el acetaminofén (paracetamol) NO son analgésicos seguros para un perro que cojea. El ibuprofeno y el naproxeno causan úlceras en el estómago y daño en los riñones en dosis que muchas personas creen inofensivas, y el acetaminofén daña el hígado y la sangre. En Colombia y en muchos países de la región estos medicamentos se compran sin receta, así que la tentación de automedicar al perro es alta: no lo haga. Tampoco le dé a un animal el medicamento de otro: los antiinflamatorios para perros son peligrosos en los gatos, y la etiqueta aprobada del carprofeno para perros dice expresamente que no se use en gatos y que se llame de inmediato al veterinario si un gato lo llega a ingerir. Y cuando su perro ya tenga un medicamento formulado, llame a su veterinario ANTES de dar, suspender, cambiar, agregar o duplicar cualquier dosis. Sobre el tratamiento, el dato más importante es que la cirugía da mejores resultados que el reposo y los medicamentos solos. En un estudio grande con historias clínicas reales de clínicas del Reino Unido, de cada 100 perros tratados hubo aproximadamente 26 perros menos que seguían cojeando en el seguimiento a corto plazo, y aproximadamente 32 perros menos en el seguimiento a largo plazo, cuando se usó cirugía en lugar de manejo sin cirugía. Son diferencias en puntos porcentuales, medidas en dos momentos distintos, no un único rango de 26 a 32 por ciento. Ese resultado salió de comparar historias clínicas reales y no de un estudio con asignación al azar, así que es evidencia sólida, pero no es una prueba definitiva. La mayoría de los perros vuelve a caminar con comodidad y a llevar una vida normal cuando se estabiliza la rodilla y completan su rehabilitación, y usted también merece saber el resto: la artrosis de esa rodilla continúa de todos modos, una minoría de perros tiene una complicación quirúrgica que requiere más tratamiento, y cerca de 1 de cada 5 perros mayores y de talla mediana a grande se rompe después el ligamento de la otra rodilla. Dos advertencias más que le ahorran dinero y tiempo: los suplementos de glucosamina y condroitina NO mostraron efecto para el dolor en la revisión más grande de la evidencia y no deben usarse como razón para aplazar la cirugía; y si le ofrecen omega-3 después de la cirugía, sepa que en un estudio aleatorizado de TPLO los perros que recibieron el alimento enriquecido con omega-3 tuvieron menos progresión de artrosis pero una proporción significativamente MENOR cicatrizó por completo la osteotomía a las 8 y a las 24 semanas; los autores dijeron que no quedó claro qué importancia clínica tiene esa cicatrización más lenta. Es un intercambio que se conversa, no se esconde.
Qué podría notar
- Cojea de una pata trasera, sobre todo después de hacer ejercicio o al levantarse de una siesta
- Levanta una pata trasera o apenas apoya los dedos en el piso
- Chilla de repente mientras juega o al resbalarse, y después empieza a cojear
- Se sienta con la pata adolorida estirada hacia un lado, en lugar de doblarla debajo del cuerpo
- Le cuesta levantarse, subirse al carro o subir escaleras
- Se escucha un chasquido o un clic en la rodilla cuando camina
- La rodilla se ve hinchada por dentro, o el muslo de esa pata se ve más delgado que el de la otra
- Cojea por temporadas durante varias semanas y de pronto empeora mucho
- Si su perro ya está tomando un antiinflamatorio (AINE): vómito, diarrea, materia fecal negra o como alquitrán, falta de apetito, cansancio inusual, encías o ojos amarillos, o que de repente tome mucha más agua u orine mucho más. Esas son señales del medicamento, no de la rodilla: suspenda el medicamento y llame a su veterinario.
- Señales que NO apuntan a la rodilla y necesitan otra evaluación urgente: arrastra las patas traseras, dobla los dedos hacia abajo al apoyar, le duele la espalda, o pierde el control de la orina
Estándar de atención
- Esta sección aún no está disponible en español.
Estabilización quirúrgica de la rodilla — la recomendación de primera línea para la mayoría de los perros
Aprobado / respaldado por guíasFor the majority of dogs with CCL rupture, surgical stabilisation is the intervention with the best-supported outcome. Offer it first and explain it first. It is still surgery under general anaesthesia: anaesthetic and perioperative risk is real, rises with age and comorbidity, and is the reason pre-anaesthetic examination, bloodwork and comorbidity screening come before the consent conversation rather than after it. Cost, age, comorbidity and bodyweight may still move an individual dog to non-surgical care, but that is a trade-off being accepted, not an equivalent option.
Productos nombrados: Not applicable — this step is a surgical recommendation.
Target trial emulation of VetCompass primary-care data: 615 surgically managed vs 200 non-surgically managed dogs with incident unilateral CCL rupture in 2019, adjusted by inverse probability of treatment weighting and inverse probability of censoring weighting. Risk difference for short-term lameness -25.7 percentage points (95% CI -36.7 to -15.9) and for long-term lameness -31.7 percentage points (95% CI -37.9 to -18.1), both favouring surgery. These are absolute percentage-point differences in the proportion of dogs still lame, at two separate time points — not a single 26-32% band, and not a relative 'percent fewer'. This is observational data analysed for causal inference, not a randomised controlled trial: treatment was chosen by owners and veterinarians rather than allocated, and Pegram 2023 shows that choice tracked age, comorbidity, bodyweight and insurance — the same variables through which residual confounding would run. The authors do frame their result as surgical management causing a reduction in lameness. DOG data.
- Esta sección aún no está disponible en español.
Elija la técnica quirúrgica con el cirujano; no afirme que una técnica sea superior de forma probada
Ensayo controlado en esta especieTPLO (tibial plateau levelling osteotomy) and TTA (tibial tuberosity advancement) are both accepted options, and extracapsular or lateral suture techniques remain in use particularly in smaller dogs. The honest position is that the published evidence base is not strong enough to declare a winner, though TPLO has lower reported complication rates and some objective-gait and osteoarthritis-progression data favouring it. Surgeon experience with the chosen technique is a legitimate part of the decision.
Productos nombrados: Not applicable — surgical technique selection.
Wemmers 2022 systematic review with meta-analytic approach: 72 studies of surgical CCL management; 47.2% judged low quality of evidence; only 11 blinded randomised clinical trials, of which 5 had low overall risk of bias. Both techniques considered successful; most dogs had no lameness at long-term evaluation; TTA appeared to give better osteoarthritis scores to 6 months while TPLO had fewer surgical site infections; authors conclude no method can clearly be preferred. Beer 2018 systematic review: 91 studies, 89 at the lowest evidence level; subjective gait analysis showed no difference between TPLO and TTA while objective gait analysis supported TPLO; average total/minor/major/catastrophic complication rates 15.9%/7.9%/5.2%/0.8% for TPLO and 20.8%/11.6%/13.2%/5.6% for TTA; authors state the strength of available evidence is poor. DOG data, both.
- Esta sección aún no está disponible en español.
Inspeccione y trate el menisco en el momento de la cirugía
Ensayo controlado en esta especieAssume the meniscus may be torn and plan to look. Missed medial meniscal pathology is a common reason a dog remains lame after an otherwise technically sound stabilisation, and a late meniscal tear is a recognised cause of sudden new lameness weeks to months after surgery — which is why owners must be told to bring a newly limping dog back rather than resting it at home.
Productos nombrados: Not applicable.
Retrospective study of 144 dogs with complete CCL rupture meeting inclusion criteria: 88 (61.11%) had a medial meniscal tear identified at arthrotomy. Dogs with acute lameness had a 6-fold greater risk of meniscal tear than dogs with chronic lameness, and meniscal tear prevalence was lower in dogs with excessive tibial plateau angle. This is observational prevalence data in DOGS, not a controlled trial of meniscal treatment.
- Esta sección aún no está disponible en español.
Analgesia multimodal y proactiva durante todo el perioperatorio y después
Aprobado / respaldado por guíasPain control is not an add-on to the surgery, it is part of it. The AAHA framework is proactive, preemptive and multimodal, with a tiered decision tree that prioritises the most efficacious modalities rather than layering weak ones. NSAIDs are the pharmacological backbone in dogs, with locoregional anaesthesia and opioids perioperatively. Screen before prescribing and re-screen during treatment: NSAIDs are inappropriate, or need explicit extra caution and monitoring, in dogs with pre-existing renal, hepatic, gastrointestinal or coagulation disease, in dehydration or hypotension including the intra-operative period, and in dogs receiving corticosteroids or other nephroactive drugs. Never layer two NSAIDs, never combine an NSAID with a systemic corticosteroid, and do not stack grapiprant with an NSAID — the grapiprant label itself directs that it not be given with any other oral or injectable NSAID or corticosteroid. Owners must be given the drug-specific stop rules in writing and told to call before they give, stop, change, add to or double any dose.
Productos nombrados: US FDA-approved canine analgesics relevant to this condition, with the label scope that actually applies — 'approved' is never written here unqualified. CARPROFEN: FDA-approved, oral use in dogs only, for relief of pain and inflammation of osteoarthritis and control of postoperative pain from soft tissue and orthopedic surgery; safe use in animals under 6 weeks of age not established; contraindicated in dogs with previous hypersensitivity to carprofen; the label states do not use in cats and to call a veterinarian immediately if a cat receives it. DERACOXIB (Deramaxx), FDA NADA 141-203: dogs, for osteoarthritis pain and inflammation and for postoperative orthopedic and dental surgical pain; label states 'Do Not Use in Cats'; safe use in dogs under 4 months of age not evaluated; contraindicated with known deracoxib hypersensitivity. FIROCOXIB (Previcox), FDA NADA 141-230: oral use in dogs only, for osteoarthritis pain and inflammation and control of postoperative pain; not for dogs under 12.5 lb; label cautions on use above the recommended 2.27 mg/lb (5.0 mg/kg) dose in puppies less than seven months of age; contraindicated with known firocoxib hypersensitivity. GRAPIPRANT (Galliprant), FDA NADA 141-455: dogs, for control of pain and inflammation associated with osteoarthritis; an EP4 prostaglandin receptor antagonist, mechanistically distinct from COX inhibitors; not evaluated in dogs younger than 9 months or under 8 lb (3.6 kg); contraindicated with grapiprant hypersensitivity; label directs that it not be administered with any other oral or injectable NSAID or corticosteroid. MELOXICAM: FDA-approved for use in dogs; the specific US canine label age/weight limits were not independently confirmed for this page, so read the dispensed label. ROBENACOXIB (Onsior) — JURISDICTION AND FORM MATTER: in the US the TABLETS are FDA-approved for cats only (NADA 141-320, 'For Oral Use In Cats Only', cats >=2.5 kg and >=4 months, maximum 3 days), while the INJECTION (FDA NADA 141-443) is approved for both cats and dogs but in dogs only for control of postoperative pain and inflammation associated with SOFT TISSUE surgery, in dogs >=4 months, for a maximum of 3 days. There is therefore no US robenacoxib approval for canine osteoarthritis or for canine orthopaedic surgery, and the canine injection label warns: do not use for more than 3 days, and serious adverse events including hepatopathy have been reported with long-term (28-day) use of Onsior tablets in dogs. Robenacoxib is separately authorised for dogs in the EU; an EU authorisation is not an FDA approval. All FDA canine NSAID labels checked here direct that the product not be given together with another NSAID or a corticosteroid.
2022 AAHA Pain Management Guidelines for Dogs and Cats — consensus guideline. Primary-care prescribing habits: in a canine ELBOW joint disease VetCompass cohort — used here only as a proxy for how primary-care veterinarians actually prescribe, not as CCL-specific evidence — NSAIDs were used in 544/616 cases (88.31%) and tramadol in 121 (19.64%) (O'Neill 2020, PMID 32835227). One caution specific to CCL recovery: a randomised controlled trial of 30 dogs randomised to deracoxib 1-2 mg/kg once daily or no treatment DURING INTENSE REHABILITATION after TPLO found no difference in lameness, range of motion or thigh circumference at 3, 5 and 7 weeks, and the authors concluded each patient should be assessed individually. This trial does NOT say post-operative pain relief is optional — it tested whether adding an NSAID through weeks of intense rehabilitation improved recovery, and found it did not. Perioperative analgesia remains non-negotiable. DOG data.
- Esta sección aún no está disponible en español.
Manejo del peso y control de la condición corporal de por vida
Aprobado / respaldado por guíasEvery kilogram comes off the operated joint and off the other stifle. Body condition score and muscle condition score belong at every visit, with an individualised nutrition plan and, where needed, a therapeutic weight-loss diet. Do it safely: weight loss should be gradual and veterinary-supervised, commonly targeted at roughly 1-2% of body weight per week, using a diet formulated to stay complete at a reduced calorie intake. Crash dieting and unbalanced home-prepared restriction diets are not a shortcut — simply feeding less of a maintenance food, or of a home-cooked ration, risks protein and micronutrient deficiency and lean-muscle loss in exactly the dog that needs its quadriceps. The AAHA guideline also addresses the communication problem directly, because owners often hear dietary advice as a judgment of their own care.
Productos nombrados: No canine weight-loss drug is currently marketed in the United States. One was FDA-approved — dirlotapide (Slentrol), a canine obesity-management drug, confirmed as a real FDA-regulated canine product in FDA's animal adverse event database (2,807 canine reports) — and it has been discontinued and is no longer marketed. No GLP-1 receptor agonist is approved for dogs by the FDA or by any other regulator located, and none should be implied to be available or appropriate for dogs.
2021 AAHA Nutrition and Weight Management Guidelines — consensus guideline. Increasing bodyweight within a breed was associated with increased odds of CCL diagnosis (PMID 26118493), and dogs >=20 kg had increased odds of being managed surgically (PMID 36708945). DOG data.
- Esta sección aún no está disponible en español.
Rehabilitación posoperatoria estructurada y ejercicio estrictamente controlado
Ensayo controlado en esta especieA written, week-by-week plan: lead-only toileting walks, controlled range-of-motion and weight-shifting work, then graded loading, with off-lead activity withheld until the surgeon clears it. Exercise restriction in the early weeks protects the osteotomy and the meniscus; it is a safety measure, not a comfort measure — and owners deserve to be told exactly what breaking it causes. One jump off the sofa, one slip on a tiled floor, or one escape out of the front door can fail the osteotomy or the implant, fracture the tibia or tibial tuberosity, or tear the meniscus, and any of those means a second anaesthetic and a second surgery. Give owners the practical means to comply, not just the instruction: a small non-slip confinement area, a lead for every toileting trip, runners or mats on slick floors, ramps instead of stairs and car jumps, no other dogs playing in the house, and food-puzzle or scent and training work to tire the dog's brain while the leg is protected. If the dog will not settle, that is a veterinary conversation about sedation or anxiolysis, not a reason to let the dog run.
Productos nombrados: Not applicable.
Randomised prospective clinical trial, 48 dogs with unilateral CCL disease undergoing TPLO plus arthroscopy, allocated to a joint-health test diet, a control diet, or either diet plus physical rehabilitation. Dogs that underwent rehabilitation had significantly lower radiographic osteoarthritis scores over time than those that did not, through 6 months. Diet and rehabilitation were each independently associated with osteoarthritis scores. DOG data. Limitation: radiographic osteoarthritis score is a surrogate, not a function or pain endpoint.
- Esta sección aún no está disponible en español.
Suplementación con ácidos grasos omega-3 o dieta articular enriquecida con omega-3 — con las salvedades honestas
Ensayo controlado en esta especieAmong the nutraceuticals reviewed in the largest meta-analysis, omega-3 has the strongest clinical analgesic evidence in canine joint disease, with cannabidiol showing efficacy to a lesser degree; it is a reasonable long-term adjunct. Three caveats belong in the same conversation. First, specific to CCL surgery: in the randomised TPLO trial above, dogs fed the omega-3 and protein-enriched test food had lower synovial fluid PGE2 and lower osteoarthritis scores, but a significantly LOWER proportion had complete osteotomy healing at 8 and 24 weeks. The authors state the clinical relevance of the slower healing was unclear. That trade-off should be discussed, not hidden. Second, practicalities: fish oil commonly causes soft stool, diarrhoea or vomiting and carries a real calorie load that works directly against the weight-loss step, so it must be counted into the daily ration rather than added on top; high doses may affect platelet function, so tell the surgical team about any fish-oil supplement well before an osteotomy rather than on the day. Third, on cannabidiol: its legal and regulatory status for animals varies by jurisdiction and it is not an FDA-approved animal drug, so it is a veterinary decision constrained by local law, not an over-the-counter default.
Productos nombrados: Not applicable — dietary. Cannabidiol is not an FDA-approved animal drug and its legality for animal use varies by jurisdiction. Do not present a supplement as a substitute for stabilisation.
PROSPERO-registered systematic review and meta-analysis (CRD42021279368), 57 articles and 72 trials across 9 nutraceutical categories in DOGS and CATS: omega-3-enriched diets, omega-3 supplements and cannabidiol (the last to a lesser degree) showed evident clinical analgesic efficacy; collagen weak; chondroitin-glucosamine showed 'a very marked non-effect'. Osteotomy-healing signal from the randomised TPLO trial, PMID 29504855.
- Esta sección aún no está disponible en español.
No dependa de productos de glucosamina y condroitina para controlar el dolor
Ensayo controlado en esta especieThese are among the most commonly recommended joint products and the evidence does not support them for pain. Saying so protects the owner's money and, more importantly, stops a supplement being used as a reason to delay surgery.
Productos nombrados: Not applicable.
The same 2022 systematic review and meta-analysis reported 'a very marked non-effect' for chondroitin-glucosamine and the authors explicitly recommend these products no longer be recommended for pain management in canine and feline osteoarthritis. DOG and CAT data.
- Esta sección aún no está disponible en español.
Manejo a largo plazo de la osteoartritis secundaria de la rodilla
Aprobado / respaldado por guíasOsteoarthritis in the affected stifle progresses whether or not surgery is done, so plan for lifelong joint care: weight, controlled conditioning, NSAIDs as needed, and — where pain persists despite the above — bedinvetmab may be considered. Two limits belong on the same line. Adequate data do not exist to support giving bedinvetmab and an NSAID at the same time: the FDA Freedom of Information Summary for NADA 141-562 states that a 2-week laboratory study in young healthy Beagles given one high-end-of-band Librela injection plus 14 days of an injectable NSAID had no significant findings but 'did not provide sufficient data to support the safety of concurrent use of Librela and NSAIDs'. Combining them is therefore a case-by-case veterinary decision with monitoring, never a default stack. And efficacy is not settled: the two pivotal field studies split, with the US study missing its own pre-specified Day-28 primary endpoint. Report the post-marketing safety record and the rapidly-progressive-osteoarthritis concern honestly rather than describing the product as risk-free.
Productos nombrados: BEDINVETMAB (Librela), FDA-approved 5 May 2023 under NADA 141-562, Zoetis Inc., for control of pain associated with osteoarthritis in dogs; given by subcutaneous injection once monthly, dosed at a minimum 0.23 mg/lb (0.5 mg/kg) by weight band, administered in the clinic. Separately authorised in the European Union (EMA procedure EMEA/V/C/005180; CVMP positive opinion 9 September 2020) — an EU authorisation is not an FDA approval and vice versa. Label and FOI limits that must travel with the name: adequate data do not exist to support concurrent use with an NSAID; women who are pregnant, trying to conceive or breastfeeding must take extreme caution to avoid accidental self-injection because of reproductive and developmental toxicity of anti-NGF antibodies in nonhuman primates; and the pivotal field studies excluded dogs with a CCL rupture in the preceding 6 months. See also the rapidly-progressive-osteoarthritis concern under evidence.
Librela (bedinvetmab), a caninised anti-nerve-growth-factor monoclonal antibody, was approved by the FDA on 5 May 2023 under NADA 141-562 (Zoetis Inc.) for the control of pain associated with osteoarthritis in dogs; it is separately authorised in the European Union, where the CVMP positive opinion was adopted 9 September 2020 (EMA procedure EMEA/V/C/005180). EFFECTIVENESS, as reported in the FDA FOI: in the US field study the difference in CBPI treatment success at the pre-specified Day-28 primary endpoint was NOT statistically significant (48.0% Librela vs 36.1% control, P = 0.0719), while the EU field study did meet significance at Day 28 (P = 0.0018); success rates in the Librela arms were higher at Day 42 than Day 28 in both studies and were maintained through Day 84. Note for this page specifically: both pivotal field studies EXCLUDED dogs whose cranial cruciate ligament rupture had occurred less than 6 months before enrolment, so the pivotal evidence is not evidence in the acute post-CCL-rupture dog. PHARMACOVIGILANCE: 18,102,535 doses sold globally between 1 February 2021 and 30 June 2024 with 17,162 adverse events reported in dogs — about 9.5 reported events per 10,000 DOSES SOLD, not per dog treated. Because bedinvetmab is given monthly, the risk to an individual dog across a course of treatment is higher than the per-dose figure implies, and a spontaneous-reporting system with a sales denominator systematically under-counts events. The most frequently reported terms were lack of efficacy (highest rate, 1.70/10,000 doses), then polydipsia, ataxia, polyuria/pollakiuria, anorexia, lethargy, death and emesis; the authors classify these as rare or very rare, and the report is authored substantially by the marketing authorisation holder (Monteiro 2025, PMID 40343372). RAPIDLY PROGRESSIVE OSTEOARTHRITIS: a 2026 JAVMA review argues bedinvetmab raises safety concerns including rapidly progressive osteoarthritis and warrants vigilant adverse event reporting, describing irreversible and often catastrophic joint destruction, progressive osseous collapse and fractures occurring within months, and calling for baseline and follow-up examinations, standardised imaging, diligent adverse event reporting and documented informed consent. Its evidentiary basis is explicitly mixed: NGF inhibition is associated with rapidly progressive osteoarthritis in HUMANS, RODENTS and RABBITS — which prevented regulatory approval of human anti-NGF antibodies — plus EMERGING canine clinical signals rather than a completed canine trial. That cross-species basis must be stated whenever the concern is raised (von Pfeil 2026, PMID 42361372). USER SAFETY: the FDA FOI states that women who are pregnant, trying to conceive, or breastfeeding should take extreme caution to avoid accidental self-injection, because NGF is important in normal fetal nervous system development and laboratory studies in nonhuman primates have shown human antibodies to NGF can cause reproductive and developmental toxicity. CONTEXT, canine: appendicular osteoarthritis has an annual period prevalence of 2.5% (95% CI 2.4-2.5) in UK primary-care dogs, about 200,000 dogs a year, and affects an estimated 11.4% of an affected dog's lifespan (Anderson 2018, PMID 29618832). DOG data throughout.
- Esta sección aún no está disponible en español.
Manejo no quirúrgico como una decisión deliberada e informada — no como una alternativa equivalente
Ensayo controlado en esta especieSome dogs will be managed without surgery: advanced age, significant comorbidity, anaesthetic risk, or cost. That is legitimate, and those dogs deserve a real plan — weight loss, sustained multimodal analgesia with the NSAID screening and stop rules spelled out for the owner, controlled conditioning and physiotherapy, and scheduled rechecks. What they do not deserve is being told it is just as good. The causal-inference data say it is not.
Productos nombrados: Same canine analgesic list, label scope and contraindications as the analgesia step; no drug substitutes for stabilisation.
Pegram 2024 (PMID 38503655): surgically managed dogs had 25.7 and 31.7 percentage points lower absolute risk of short- and long-term lameness respectively. Pegram 2023 (PMID 36708945) describes the real-world decision pattern: dogs >=9 years and dogs with a non-orthopaedic comorbidity at diagnosis had reduced odds of surgical management, while insured dogs and dogs >=20 kg had increased odds — i.e. the choice tracks age, comorbidity and ability to pay. DOG data.
- Esta sección aún no está disponible en español.
Aconseje sobre la otra rodilla, y vigílela
Ensayo controlado en esta especieGive the owner a real number and a real timeframe rather than a vague warning, and tell them what second-side rupture looks like so they present early. There is no intervention proven to prevent it, and tibial plateau angle is not a screening test for it.
Productos nombrados: None. Note specifically that intra-articular hyaluronic acid plus oral doxycycline after arthroscopic lavage did not protect the contralateral ligament in the one study that tested it.
Two separate, non-comparable metrics, kept separate on purpose. (1) Cross-sectional retrospective study of 831 dogs >=15 kg and >=8 years at first rupture, median follow-up over 112.7 months: 19.1% (159/831; 95% CI 16.6-22.0) ruptured the contralateral CCL, and AMONG THOSE THAT DID the median interval to second-side diagnosis was 12.9 months (IQR 6.5-24.3). Age and Golden or Labrador Retriever breed were significantly associated, and risk decreased with increasing age (Murphy 2023, PMID 37487534). (2) Separately, in a REFERRAL cohort of 380 dogs of ALL AGES with unilateral non-contact rupture, median survival of the contralateral ligament was 947 days; increasing tibial plateau angle shortened survival, increasing age at diagnosis lengthened it, and survival was reduced in neutered dogs (Muir 2011, PMID 21998650). Different populations, different estimands — 12.9 months and 947 days are not competing estimates of the same quantity. In that same study a disease-modifying protocol of arthroscopic lavage, intra-articular hyaluronic acid and oral doxycycline (n=16) did NOT significantly influence contralateral ligament survival. On TPA: within the usual clinical range (mostly <35 degrees) it was not a useful predictor of which individual dog would rupture the other side in a 150-dog series (Cabrera 2008, PMID 18341447), even though steeper angles were associated with shorter contralateral survival at population level in Muir 2011. DOG data throughout.
2022 AAHA Pain Management Guidelines for Dogs and Cats — American Animal Hospital Association
Cómo se diagnostica
- Gait assessment plus a full orthopaedic examination with adequate restraint or sedation: cranial drawer and tibial compression tests, medial buttress, joint effusion, pain on stifle extension, and quadriceps or hamstring atrophy. Muscle guarding in an awake dog can mask instability, so sedation is often needed to reach a confident answer.
- Examine and document the contralateral stifle at the same visit. Bilateral disease is common and it changes both the surgical plan and the prognosis conversation.
- Rule out the differentials that mimic CCL disease: medial patellar luxation, isolated meniscal injury, caudal cruciate or collateral ligament injury, long digital extensor avulsion, immune-mediated or septic arthritis, joint neoplasia including osteosarcoma, hip dysplasia, and lumbosacral or iliopsoas pain. Separate out the conditions that are not orthopaedic at all: acute hind-limb paresis with knuckling, a painful spine or urinary incontinence is a spinal cord emergency, not a stifle case.
- Orthogonal sedated stifle radiographs (mediolateral and craniocaudal) for effusion, osteophytosis, cranial tibial translation, and to exclude neoplasia and avulsion fracture. Measure the tibial plateau angle if an osteotomy is planned.
- Plan to inspect the meniscus rather than rely on palpation: a medial meniscal tear was present in 61.1% (88/144) of dogs with complete CCL rupture at the time of arthrotomy (Bertorelli 2025, PMID 40141000). On tibial plateau angle, hold two findings together without collapsing them: TPA within the usual clinical range (mostly <35 degrees) was NOT a useful predictor of which individual dog would rupture the contralateral ligament (Cabrera 2008, PMID 18341447), while at population level increasing TPA was associated with shorter contralateral ligament survival (Muir 2011, PMID 21998650), and excessive TPA was associated with FEWER meniscal tears (Bertorelli 2025). The practical conclusion is that TPA is a surgical planning measurement, not a screening test for the second knee.
- Baseline pre-anaesthetic assessment: physical examination, bloodwork, and comorbidity screening appropriate to age. This is not a formality — it is how anaesthetic and surgical risk is quantified for this individual dog, and it is the same risk that legitimately moves some dogs to non-surgical management. Record body weight, body condition score and a baseline owner-completed pain and function score so response can be measured rather than remembered.
- Advanced imaging (CT or MRI) or arthroscopy where the diagnosis remains unclear or concurrent intra-articular pathology is suspected.
Dónde encaja un biológico
Nuestro propio producto, calificado con la misma regla
Respuesta corta: aquí hay evidencia preliminar. Prometedora, no probada.
En los perros con enfermedad del ligamento cruzado craneal, el tratamiento respaldado por la evidencia de inferencia causal es la cirugía, no un producto biológico. La única evidencia controlada en la propia especie para un biológico en esta enfermedad es un solo estudio piloto aleatorizado y doble ciego con 20 perros, en el que un secretoma de células madre caninas derivadas de tejido adiposo, aplicado dentro de la articulación al final de una TPLO, se asoció con una mejoría más temprana en los puntajes de cojera y de dolor y con menor progresión de la artrosis en las radiografías, sin ninguna diferencia en la medición objetiva de actividad con acelerómetro. Ningún producto de exosomas y ningún péptido tiene evidencia clínica publicada de eficacia en esta enfermedad en perros, y no existe ningún estudio clínico publicado de eficacia de exosomas de cordón umbilical en perros ni en gatos. Hay que nombrar siempre al ente regulador: en Estados Unidos la FDA no ha aprobado ningún producto de células, tejidos o derivados celulares para animales, así que esos productos son medicamentos veterinarios nuevos no aprobados; DogStem sí está autorizado en la Unión Europea (contiene células madre EQUINAS de cordón umbilical que se inyectan en PERROS), pero esa autorización europea no equivale a una aprobación de la FDA y su propia ficha técnica dice que la eficacia se demostró solo en codo o cadera y que no hay datos de eficacia en otras articulaciones. Tampoco se puede decir que estas células sean 'inmunoprivilegiadas' ni que no causen brotes de inflamación: en un ensayo controlado aleatorizado en perros, 6 de 8 perros que recibieron células equinas y 5 de 8 que recibieron células caninas desarrollaron anticuerpos contra las células aplicadas, y los propios autores concluyeron que las células madre mesenquimales son inmunotolerantes, no inmunoprivilegiadas.
Qué existe
Esta sección aún no está disponible en español.SCOPE FIRST: no biologic replaces stabilisation in this condition. The only controlled in-species evidence for a biologic in canine CCL disease is one trial, and it is an adjunct-to-surgery trial. (1) ADJUNCT TO TPLO, CELL-DERIVED SECRETOME — Carrera et al. 2026, Vet Res Commun 50(5), PMID 42287504, DOI 10.1007/s11259-026-11343-9: prospective, double-blind, randomised PILOT trial in DOGS. 20 client-owned dogs, 10 per arm, given 250 ug of allogeneic canine adipose-derived stem cell enriched secretome or placebo intra-articularly at the end of TPLO, followed to 150 days. Median lameness score fell from 3 to 1 and stifle pain from 2 to 0 by day 15 in the treated arm versus day 60 and day 90 respectively in controls; radiographic osteoarthritis score fell from 1 to 0 in the treated arm while progressing from 1 to 2 in controls; ultrasonographic joint effusion improved from 30 days; radiographic bone-healing score at 30 days was higher in the treated arm (mean differences 1.9 on a 10-point and 1 on a 5-point scale). CRITICALLY: the objective outcome was null — no differences occurred in accelerometry outcomes, i.e. measured activity levels did not differ between arms. n=10 per arm, ordinal medians, single centre, pilot; the authors frame the result as suggesting potential as a biologic adjunct, not as established benefit. (2) CANINE OA MSC RCTs, WRONG JOINT — five randomised controlled trials of intra-articular MSC exist for canine osteoarthritis (Black 2007 PMID 18183546; Harman 2016 DOI 10.3389/fvets.2016.00081, n=74, owner CSOM success 79.2% treated vs 55.4% placebo, p=0.029; Kim 2019 DOI 10.3389/fvets.2019.00474, n=68, CBPI success 46% vs 14% at 6 months but no differences in peak vertical force of the affected limb over time in either group; Punzon 2022 PMID 36198051, DOI 10.2460/javma.22.06.0237, n=80 xenogeneic equine UC-MSC; Kim 2022 DOI 10.3389/fvets.2022.890704, n=14, in which hyaluronic acid OUTPERFORMED MSC at weeks 24 and 36). Every one of these studied ELBOW or HIP osteoarthritis, not the stifle. Note the placebo response in Harman 2016: more than half of placebo dogs were scored as successes by their owners. (3) DOGSTEM — the one authorised product, European Commission marketing authorisation 17 June 2022 via EMA procedure EMEA/V/C/005829, MA number EU/2/22/285, MAH EquiCord S.L.; it contains EQUINE umbilical cord MSCs injected into DOGS (xenogeneic). Its pivotal trial reported best results at 8 weeks, with 63% of patients improving on force-plate gait analysis, 77% improving on orthopaedic examination and 65% of owners considering quality of life improved, and 59% of owners reporting an effect lasting longer than 6 months at 18-month follow-up; the trial was authored by the marketing authorisation holder. The SmPC is explicit: efficacy was demonstrated only in ELBOW or HIP, no efficacy data are available regarding treatment of other joints, single dose only, and safety was investigated only in dogs >=1 year and >15 kg. DogStem is therefore not evidence for stifle disease, and an EMA authorisation confers no US marketing right — it is EU-authorised and NOT FDA-approved. (4) SURGICAL-SITE MSC WORK IN CCL DOGS — small and weak: 9 dogs, MSC implanted in the TTA osteotomy site, 36.45% greater mean ossification at 30 days (p<=0.033) and no difference at other timepoints, with no reduction in overall recovery time (PMID 29900517, DOI 10.1186/s40634-018-0130-z); a small non-randomised TTA pilot across four groups (PMID 33656452, DOI 10.1556/004.2020.00063); a single-dog case report of infrapatellar fat pad stem cells after CCL reconstruction (PMID 41902883); and a single-dog radiolabelled biodistribution report showing 40.61% higher uptake of intravenous xenogeneic equine MSC in the affected stifle than the healthy contralateral joint (PMID 36504848) — a homing observation, not an efficacy result. (5) IMMUNOGENICITY — Punzon et al. Front Vet Sci 2023;10:1098029, PMID 37266387: randomised controlled safety trial in 24 healthy police working dogs, 1:1:1, xenogeneic equine UC-MSC vs allogeneic canine adipose MSC vs placebo, intra-articular, single and repeated dosing. No adverse events were detected, but 6/8 equine-MSC dogs and 5/8 canine-MSC dogs developed antibodies against the cells they received, and 1/8 placebo dogs had pre-existing reactive antibodies. The CELISA was qualitative, so titres were not quantified. The authors' own conclusion is that MSCs are immune-tolerant rather than immune-privileged. Both EQUINE and CANINE MSCs raised antibodies, so neither 'immune-privileged' nor 'zero-flare' is a defensible claim for either.
Qué no se ha demostrado
Esta sección aún no está disponible en español.There is NO randomised, placebo-controlled, objectively-outcomed exosome or extracellular-vesicle trial in dogs for any indication, and none in canine CCL disease or stifle osteoarthritis specifically — there is no published in-vivo clinical efficacy study of umbilical-cord exosomes in dogs or cats at all. A targeted PubMed search combining EV/exosome with dog/cat plus randomised/double-blind/clinical-trial plus objective outcomes returned zero results; the only in-vivo intra-articular canine EV-containing study located is an n=3 safety study of an allogeneic MSC lyosecretome in knee or elbow osteoarthritis (PMID 34828003), which reported no clinically significant local or systemic adverse response and was not designed to show efficacy. There is NO peptide with controlled efficacy evidence in dogs, cats or horses for this or any condition — BPC-157 has only a beagle pharmacokinetic study (PMID 36588717; elimination half-life under 30 minutes, IM bioavailability 45-51%, no efficacy endpoint), TB-500 (thymosin beta-4) has only an equine anti-doping detection paper and is named-banned by the FEI as an anabolic, and neither has any companion-animal efficacy data. There is NO cell, exosome or peptide product proven to prevent contralateral rupture — the one study that tested a disease-modifying protocol (arthroscopic lavage plus intra-articular hyaluronic acid plus oral doxycycline) found no effect on contralateral ligament survival (PMID 21998650). There is NO evidence that any biologic can restore a ruptured cranial cruciate ligament, regenerate it, or make stabilisation unnecessary. There is NO MSC or exosome efficacy trial in the canine STIFLE — all five canine OA RCTs studied elbow or hip, and DogStem's own SmPC states no efficacy data exist for other joints. There is NO biodistribution data for DogStem: its SmPC states that the extent of persistence of the equine umbilical cord MSCs from this product after intra-articular administration to dogs is not known. In the UNITED STATES no animal cell, tissue or cell-derived product is FDA-approved — FDA CVM states plainly that no ACTPs are FDA-approved — so such products are unapproved new animal drugs; 'acellular' or 'cell-free' framing does not exempt them, because GFI #218 defines a cell-based product as one containing, consisting of, or DERIVED FROM cells, and FDA CVM has issued warning letters treating conditioned media as an unapproved new animal drug. Jurisdiction must always be named: DogStem is EU-authorised by the European Commission on EMA assessment and is not FDA-approved; robenacoxib is EU-authorised for dogs while in the US it is FDA-approved for dogs only as an injection for soft-tissue-surgery pain for up to 3 days; bedinvetmab is both FDA-approved and EU-authorised. Finally, 'immune-privileged' is NOT a defensible claim for any of these products in dogs.
Fuentes
- The only controlled in-species biologic trial in canine CCL disease (adjunct to TPLO, secretome, n=20 pilot, objective outcome null) — Carrera ALC, Minto BW, Alcantara BM, Previtali DAC, Faustino RCS, Tavares ABL, Doiche DP, Nogueira C, Brunel HSS, Pereira RW, Alievi MM, Dias LGGG, Malard PF. Intra-articular injection of allogeneic canine adipose-derived stem cell enriched secretome in dogs undergoing tibial plateau leveling osteotomy: a prospective double-blind and randomized pilot trial. Vet Res Commun. 2026;50(5). PMID 42287504. DOI 10.1007/s11259-026-11343-9 https://doi.org/10.1007/s11259-026-11343-9
- MSCs are immune-tolerant, not immune-privileged: both equine and canine MSCs produced anti-donor antibodies in recipient dogs — Punzon E, Garcia-Castillo M, Rico MA, Padilla L, Pradera A. Local, systemic and immunologic safety comparison between xenogeneic equine umbilical cord mesenchymal stem cells, allogeneic canine adipose mesenchymal stem cells and placebo: a randomized controlled trial. Front Vet Sci. 2023;10:1098029. PMID 37266387. DOI 10.3389/fvets.2023.1098029 https://doi.org/10.3389/fvets.2023.1098029
- The pivotal DogStem trial — xenogeneic EQUINE UC-MSC in DOGS, elbow and hip only, sponsor-authored — Punzon E, Salguero R, Totusaus X, Mesa-Sanchez C, Badiella L, Garcia-Castillo M, Pradera A. Equine umbilical cord mesenchymal stem cells demonstrate safety and efficacy in the treatment of canine osteoarthritis: a randomized placebo-controlled trial. J Am Vet Med Assoc. 2022;260(15):1947-1955. PMID 36198051. DOI 10.2460/javma.22.06.0237 https://doi.org/10.2460/javma.22.06.0237
- DogStem regulatory record — EU-authorised (not FDA-approved), equine cells in dogs, efficacy limited to elbow and hip — European Medicines Agency. DogStem (equine umbilical cord-derived mesenchymal stem cells), EPAR and SmPC, procedure EMEA/V/C/005829, European Commission marketing authorisation EU/2/22/285 issued 17 June 2022, MAH EquiCord S.L. This is a European Union authorisation and confers no United States marketing right. https://www.ema.europa.eu/en/medicines/veterinary/EPAR/dogstem
- Canine OA MSC RCT with the largest reported effect — and a 55.4% placebo response on the owner-scored primary endpoint (elbow/hip, not stifle) — Harman R, Carlson K, Gaynor J, Gustafson S, et al. A Prospective, Randomized, Masked, and Placebo-Controlled Efficacy Study of Intraarticular Allogeneic Adipose Stem Cells for the Treatment of Osteoarthritis in Dogs. Front Vet Sci. 2016;3:81. DOI 10.3389/fvets.2016.00081 https://doi.org/10.3389/fvets.2016.00081
- The canine OA MSC trial the industry does not cite — hyaluronic acid outperformed MSC, and 6 of 7 joint flares were in the MSC arm — Kim S, Elam L, Johnson V, Hess A, et al. Intra-Articular Injections of Allogeneic Mesenchymal Stromal Cells vs. High Molecular Weight Hyaluronic Acid in Dogs With Osteoarthritis: Exploratory Data From a Double-Blind, Randomized, Prospective Clinical Trial. Front Vet Sci. 2022;13:890704. DOI 10.3389/fvets.2022.890704 https://doi.org/10.3389/fvets.2022.890704
- MSC in the TTA osteotomy site in CCL-affected dogs — n=9, 36.45% greater ossification at 30 days only, no reduction in recovery time — Rocha Dos Santos C, da Rocha Filgueiras R, Furtado Malard P, Rodrigues da Cunha Barreto-Vianna A, Nogueira K, da Silva Leite C, Maurico Mendes de Lima E. Mesenchymal stem cells in osteotomy repair after tibial tuberosity advancement in dogs with cranial cruciate ligament injury. J Exp Orthop. 2018;5(1):17. PMID 29900517. DOI 10.1186/s40634-018-0130-z https://doi.org/10.1186/s40634-018-0130-z
- US regulatory status — FDA CVM states no animal cell- and tissue-based product is FDA-approved — FDA Center for Veterinary Medicine. Cell and Tissue Products for Animals: 'Currently, no ACTPs are FDA-approved.' See also CVM GFI #218, Cell-Based Products for Animal Use (June 2015), which defines a cell-based product as one containing, consisting of, or derived from cells. https://www.fda.gov/animal-veterinary/biotechnology-products-cvm
- No published in-vivo clinical efficacy evidence for exosome/EV products in dogs; the only intra-articular canine study located is an n=3 safety report — Mocchi M, Bari E, Dotti S, Villa R, Berni P, Conti V, Del Bue M, Squassino GP, Segale L, Ramoni R, Torre ML, Perteghella S, Grolli S. Canine Mesenchymal Cell Lyosecretome Production and Safety Evaluation after Allogenic Intraarticular Injection in Osteoarthritic Dogs. Animals (Basel). 2021;11(11):3271. PMID 34828003. DOI 10.3390/ani11113271. See also FDA, Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes: 'There are currently no FDA-approved exosome products.' https://doi.org/10.3390/ani11113271
- BPC-157 in dogs — pharmacokinetics only, no efficacy endpoint in any veterinary species — He L, et al. Pharmacokinetic study of BPC-157 in beagle dogs. Front Pharmacol. 2022;13:1026182. PMID 36588717. DOI 10.3389/fphar.2022.1026182. Elimination half-life under 30 minutes; IM bioavailability 45-51%. https://doi.org/10.3389/fphar.2022.1026182
Seguimiento de la respuesta
Cómo saber si está funcionando
Canine Brief Pain Inventory (CBPI) — owner-completed Pain Severity Score and Pain Interference Score — paired where possible with an objective measure (force-plate peak vertical force, or accelerometry) and a Client-Specific Outcome Measure (CSOM) in which the owner names three activities that matter to their own dog and scores each one. The objective measure matters: in canine joint-biologic trials, owner and veterinarian subjective scores have repeatedly improved while force-plate and accelerometry outcomes did not.
Brown DC, Boston RC, Coyne JC, Farrar JT. Ability of the canine brief pain inventory to detect response to treatment in dogs with osteoarthritis. J Am Vet Med Assoc. 2008;233(8):1278-83. PMID 19180716. DOI 10.2460/javma.233.8.1278. In that double-blind randomised placebo-controlled trial of 70 dogs, CBPI detected significantly greater improvement in pain severity and pain interference with carprofen than with placebo. A validated French-language version also exists (Ragetly GR, Massey L, Brown DC. Vet Anaesth Analg. 2019;46(5):667-672. PMID 31301964. DOI 10.1016/j.vaa.2019.04.001).
Frecuencia sugerida: Baseline before any treatment. Then at the post-operative recheck around day 14, at week 6, week 8 (with the surgeon's radiographic osteotomy-healing check at whatever interval that surgeon specifies), week 12, then every 3 months through the first year, then twice yearly for life because the stifle osteoarthritis is permanent. Re-score immediately if there is any sudden new lameness, on either hind limb. For a dog receiving bedinvetmab, record a baseline orthopaedic examination and baseline imaging and repeat them on a defined schedule, so that a rapidly progressive change would be detected rather than assumed.
Preguntas que puede responder en casa
- On a scale of 0 to 10, how bad was your dog's knee pain at its worst this week?
- When your dog is standing still, is she putting full weight on that leg, some weight, or none?
- How far can she walk now before she slows down or starts to limp?
- Can she get up from lying down, climb the stairs, and get into the car without help?
- Compared with your last check-in, is she using that leg more, the same, or less?
- Have you noticed any new limping on the OTHER back leg?
- If she is on an anti-inflammatory: any vomiting, diarrhoea, black or tarry stool, loss of appetite, unusual tiredness, yellow gums or eyes, or drinking and urinating more than usual?
- Has she had any unsupervised running, jumping or slipping since the last check-in?
Última revisión: 2026-09-20 · Cada afirmación de esta página lleva una fuente que usted puede verificar. Si alguna no se sostiene, díganoslo y la corregiremos. science@petsmartmeds.com
Cree un perfil para su mascota
Cuéntenos qué está enfrentando y el sitio le mostrará solo lo que aplica.